Financial Performance - The company's revenue for the year ended December 31, 2024, was HKD 70,509,000, a decrease of 66.7% compared to HKD 211,985,000 in 2023[3] - The gross loss for the year was HKD 4,940,000, compared to a gross profit of HKD 34,324,000 in the previous year[3] - Operating loss increased to HKD 143,048,000 from HKD 127,674,000 year-over-year[3] - The total comprehensive loss for the year was HKD 268,982,000, compared to HKD 174,253,000 in 2023, representing a 54.3% increase[4] - Basic and diluted loss per share was HKD 0.205, compared to HKD 0.099 in the previous year[4] - The group reported a loss of approximately HKD 251,854,000 for the year ended December 31, 2024[14] - The company reported a total loss before tax of HKD 252,797,000 for the year ended December 31, 2024, compared to a loss of HKD 142,025,000 in 2023[27][29] - The group recorded a net loss attributable to shareholders of approximately HKD 198,146,000 in 2024, an increase from HKD 95,447,000 in 2023[69] Assets and Liabilities - Total assets decreased to HKD 529,955,000 from HKD 662,362,000, a decline of 20.0%[5] - Total equity decreased to HKD 242,388,000 from HKD 490,726,000, a drop of 50.6%[6] - The total liabilities of the company as of December 31, 2024, were HKD 287,567,000, compared to HKD 171,636,000 in 2023[27][29] - As of December 31, 2024, the group's current liabilities exceeded its current assets by approximately HKD 129,519,000[14] - The total current assets decreased from HKD 39,636,000 in 2023 to HKD 25,416,000 in 2024, a decline of about 36%[35] Revenue Breakdown - Revenue from medical laboratory testing and health check services was HKD 39,158,000, down from HKD 192,910,000, indicating a decrease of about 79.7%[23] - Insurance brokerage services revenue increased to HKD 30,600,000 from HKD 18,163,000, reflecting a growth of approximately 68.4%[23] - The segment loss for the medical and healthcare services division was HKD 100,150,000 for the year ended December 31, 2024[27] - The overall demand for medical laboratory testing and health check services was weaker than expected in fiscal year 2024, attributed to local consumption recovery challenges post-pandemic[52] Financing and Capital Structure - The company has issued convertible bonds amounting to HKD 41,635,000, which were not present in the previous year[6] - The company plans to redeem USD 4,000,000 (approximately HKD 31,400,000) of the convertible bonds on December 17, 2024[40] - A new convertible bond issuance of USD 6,000,000 (approximately HKD 47,100,000) occurred on December 27, 2024, with an initial conversion price of HKD 1.20 per share[41] - The company has secured loans from controlling shareholders amounting to approximately HKD 24,772,000 as of December 31, 2024, with a fixed interest rate of 10%[90] - The group is actively seeking alternative financing and loans to meet its current financial obligations and future operational and capital expenditures, having secured approximately HKD 6,000,000 in additional loans as of the financial statement approval date[16] Impairment and Losses - The company reported a net impairment loss on property, plant, and equipment of HKD 52,713,000, compared to HKD 16,186,000 in 2023[3] - The impairment loss recognized for construction projects due to damage was approximately HKD 52,713,000[24] - The group recognized impairment losses of approximately HKD 13,374,000 and HKD 2,584,000 for intangible assets and right-of-use assets, respectively, related to the acquisition of DVF[67] Strategic Initiatives and Future Plans - The group has entered into a strategic cooperation framework agreement with Shenzhen Huada Gene Technology Co., Ltd., and an investment intention letter with investors for a potential investment of RMB 20 million to 30 million in Pengbo (Hainan)[16] - The company aims to be the first provider of boron neutron capture therapy services in Greater China, targeting inoperable, locally advanced, or locally recurrent head and neck cancer patients[85] - The company has launched a series of early health screening tests, including diabetes and HPV, to capitalize on the increased public awareness of health due to the pandemic[82] - The company continues to develop its anti-tumor cell therapy products, with clinical trials for its CAR-T drug progressing as planned[83] Governance and Compliance - The board of directors includes three executive directors and three independent non-executive directors[129] - The company has maintained compliance with the GEM listing rules regarding public float requirements[128] - The independent auditor's report indicated a significant uncertainty regarding the group's ability to continue as a going concern[112]
中国生物科技服务(08037) - 2024 - 年度业绩